| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM197902013000502 |
| P698 | PubMed publication ID | 759868 |
| P50 | author | Hershel Jick | Q37834455 |
| P2093 | author name string | Walker AM | |
| Hunter JR | |||
| Rothman KJ | |||
| Madsen S | |||
| Watkins RN | |||
| Dinan BJ | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 218-222 | |
| P577 | publication date | 1979-02-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Replacement estrogens and endometrial cancer. | |
| P478 | volume | 300 |
| Q52875788 | A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses. |
| Q44258741 | A comparison of wax matrix and microencapsulated potassium chloride in relation to upper gastrointestinal illness requiring hospitalization |
| Q57945295 | A database worth saving |
| Q39576942 | A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women |
| Q69676884 | ADFR therapy in the prevention of bone loss after menopause |
| Q36341343 | Alternative data sources in a case-control study of conjugated estrogens and cancer. |
| Q33847788 | An assessment of the Mi-Mark endoemtrial sampling technique |
| Q30485941 | Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control |
| Q33605790 | Antibiotic-associated colitis |
| Q50851964 | Associations between physical activity and susceptibility to cancer: possible mechanisms. |
| Q45979048 | Biologic effects of equilin sulfate in postmenopausal women. |
| Q57945751 | CO-TRIMOXAZOLE TOXICITY IN CHILDREN |
| Q45081071 | Certain nonsteroidal antiinflammatory drugs and hospitalization for upper gastrointestinal bleeding |
| Q33685759 | Cigarette smoking and benign breast disease |
| Q36644808 | Combination therapy for osteoporosis with estrogen, fluoride, and calcium |
| Q32065283 | Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms |
| Q39513315 | Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment |
| Q35970729 | Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation |
| Q72475096 | Drug-Induced Cancer |
| Q57945665 | Drugs and stillbirth |
| Q71012624 | Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium |
| Q51627933 | Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication. |
| Q64356864 | Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause |
| Q36467341 | Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study |
| Q45958642 | Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). |
| Q40194265 | Endometrial carcinogenesis and its relation to oestrogens |
| Q71179638 | Endometrial disease after treatment with oestrogens and progestogens in the climacteric |
| Q43662497 | Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate |
| Q66703448 | Epidemic hepatitis B caused by commercial human immunoglobulin |
| Q36988226 | Estrogen replacement therapy (ERT) in high-risk cancer patients |
| Q37917064 | Estrogen therapy during menopause. Practical treatment recommendations |
| Q35229739 | Estrogens and endometrial cancer: some answers and some further questions |
| Q40890621 | Exercise in the prevention and treatment of cancer. An update |
| Q34108842 | Hip fracture, skeletal fragility, osteoporosis and hormonal deprivation in elderly women. |
| Q24235543 | Hormonal therapy in advanced or recurrent endometrial cancer |
| Q67007434 | Hormone replacement therapy |
| Q34370222 | Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits |
| Q40877118 | Hormone replacement therapy and cancer |
| Q46938620 | Hormone replacement therapy and endometrial cancer |
| Q44304778 | Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women |
| Q24240723 | Hormone therapy for advanced or recurrent endometrial cancer |
| Q44110990 | Intermittent progestin administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate |
| Q51937198 | Learning how to control biases in studies to identify adverse effects of drugs: a brief personal history. |
| Q71658220 | Long-term follow-up is a problem |
| Q34201187 | Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes |
| Q70199870 | Management of osteoporosis |
| Q39653962 | Multistage carcinogenesis: implications for risk estimation |
| Q57945636 | NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND HOSPITAL ADMISSION FOR PERFORATED PEPTIC ULCER |
| Q66703446 | Oestrogen replacement therapy |
| Q39595387 | Oestrogen replacement therapy: physiological considerations and new applications |
| Q66703360 | Oestrogen therapy and endometrial cancer |
| Q93477989 | Oestrogen therapy and endometrial carcinoma |
| Q57608720 | Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases |
| Q55072707 | Oral contraceptives and breast cancer. |
| Q57945680 | Outpatient Drug-Induced Parenchymal Liver Disease Requiring Hospitalization |
| Q34553312 | Pharmacoepidemiology: a new discipline |
| Q39561985 | Physical activity and cancer. An epidemiological perspective |
| Q39567123 | Postmenopausal hormone replacement therapy with estrogen periodically supplemented with antiestrogen |
| Q40864441 | Postmenopausal hormone replacement: are two hormones better than one? |
| Q72072810 | Prevalence of prior hysterectomy in the Seattle-Tacoma area |
| Q28318588 | Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy |
| Q52907014 | Principles of epidemiological research on adverse and beneficial drug effects. |
| Q38506224 | Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens |
| Q40135871 | Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review |
| Q66703332 | Screening for cystic fibrosis |
| Q57945918 | Sedating drugs and automobile accidents leading to hospitalization |
| Q66703359 | Selective damage to cholinergic nerves: possible cause of postoperative ileus |
| Q55062242 | Serum equilin, oestrone, and oestradiol levels in postmenopausal women receiving conjugated equine oestrogens ('Premarin') |
| Q36215680 | Sex Steroids and Cancer in Older Women |
| Q68028791 | Statistical methods in pharmacoepidemiology. Principles in managing error |
| Q71353704 | The Isaacs cell sampler: an alternative to curettage |
| Q31048529 | The cancer question: an overview of recent epidemiologic and retrospective data |
| Q70264810 | The decreasing incidence of endometrial cancer: public health implications |
| Q57946059 | The epidemic of endometrial cancer: a commentary |
| Q39564032 | The menopause: benefits and risks of estrogen-progestogen replacement therapy. |
| Q70524803 | The pathologic features and behavior of endometrial carcinoma associated with exogenous estrogen administration |
| Q34447549 | The role of record linkage in post-marketing drug surveillance |
| Q36500604 | Use of automated data bases to study drug effects after marketing |
Search more.